Lead Therapy Trial Fuels aTyr Pharma's (ATYR) Promising Upside, Leerink Stays Bullish

aTyr Pharma Inc. (NASDAQ:ATYR) is one of the best multibagger stocks to invest in right now. On August 22, Leerink Partners’ Faisal Khurshid reiterated a Buy rating on aTyr Pharma Inc. (NASDAQ:ATYR) with a $16 price target. His view reflects optimism around the EFZO-FIT trial, which is testing efzofitimod as a potential treatment for pulmonary sarcoidosis.

Khurshid highlights that feedback from two MEDACorp key opinion leaders (KOLs) involved in the study suggests that efzofitimod could offer a safe, steroid-sparing option if the results prove favorable. He said that anecdotal cases of successful steroid tapering added to the confidence, even though the trial’s small size and blinded design limit visibility. Both KOLs highlighted the strength of patient selection and trial operations, which were structured to reduce placebo effects.

One of the KOLs had calculated the probability of success at 65-70%, slightly above Khurshid’s own 60% view. While the trial remains high-risk, Khurshid believes the potential reward justifies the Buy rating, given efzofitimod’s opportunity to address a serious unmet medical need.

aTyr Pharma Inc. (NASDAQ:ATYR) is a clinical-stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.

While we acknowledge the potential of ATYR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Shorted Stocks Right Now and 10 Best High Beta Stocks To Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.